Physician profile
Clinton Walker
NPI 1124417761
$3,266.31
in general payments reported to CMS, 2019-2025
38 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $418 · 2022: $1,143 · 2023: $616 · 2024: $600 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,705.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $494.80 | 2021-2025 | Ultomiris |
| Ucb, INC. | $258.70 | 2021-2025 | Rystiggo, Fintepla, Zilbrysq |
| Biohaven Pharmaceutical Holding Company Ltd. | $207.68 | 2022 | |
| Avanir Pharmaceuticals, INC. | $207.08 | 2021-2022 | |
| Csl Behring | $186.47 | 2021-2025 | Hizentra |
| Amgen INC. | $145.88 | 2021-2023 | Aimovig |
| Axogen | $124.98 | 2024 | Axoguard Nerve Cap, Axoguard Ha+ Nerve Protector, Axoguard Nerve Protector |
| Ferring Pharmaceuticals INC. | $120.39 | 2022-2025 | Euflexxa |
| Kyowa Kirin, INC. | $119.09 | 2022-2023 | Nourianz |
| Acorda Therapeutics, INC | $111.69 | 2021-2023 | Inbrija |
| Eisai INC. | $106.30 | 2021-2022 | |
| Amylyx Pharmaceuticals, INC. | $104.23 | 2023-2024 | Relyvrio |
| Biogen, INC. | $88.12 | 2023-2025 | Spinraza, Qalsody, Tysabri |
| Catalyst Pharmaceuticals, INC. | $82.57 | 2024-2025 | |
| Argenx US, INC. | $76.58 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clinton Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.